Identical clinical trial packages no longer secure synchronized transatlantic drug approvals.
A growing regulatory divide between the FDA and EMA splits the market access of cutting-edge therapies based on differing risk-benefit tolerances.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
It outlines how exactly identical therapeutic profile evaluations have completely diverged across transatlantic lines.
European regulators approved the therapy based on Phase 3 data while the US FDA delayed its decision, showcasing a deep transatlantic regulatory divide.
The EMA rejected a rare disease therapy that had already been successfully approved by the U.S. FDA, splitting the global market in half.
The European CHMP refused to approve narsoplimab based on the same clinical package that Omeros submitted to global regulators.